Effect of dihydroergocristine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic, and acromegalic subjects: further evidence for pituitary dopamine deficiency in these conditions.
D000172:Acromegaly / Q000097:blood*; D000236:Adenoma / Q000097:blood; D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000097:blood; D004088:Dihydroergotoxine / Q000494:pharmacology*; D004298:Dopamine / Q000172:deficiency*; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009627:Nomifensine / Q000494:pharmacology; D010902:Pituitary Gland / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000097:blood; D011388:Prolactin / Q000097:blood*
D004088:Dihydroergotoxine; D009627:Nomifensine; D007980:Levodopa; D011388:Prolactin; D013006:Growth Hormone; D004298:Dopamine